CRISPR-powered hypoallergenic beagles signal a new chapter in pet allergy relief

A New York start-up has used gene editing to create beagles that do not produce the main dog allergen, marking a potential breakthrough in allergy management and pet ownership.

A New York start-up says it has taken a first step towards reducing one of the most common pet-related allergies by using CRISPR to disable the main dog allergen in beagles.

According to a report in The CRISPR Journal, Kindred Companion Sciences engineered a pair of healthy beagle puppies, Alfie and Bailey, so they do not produce Can f 1, the lipocalin protein most closely linked to human dog allergy. The company says saliva and dander testing found no detectable Can f 1 in the pups, while skin-prick testing showed no reaction in a sensitised subject exposed to their extracts.

The work matters because dog allergy affects a substantial share of the population and often leads to rhinitis, eye irritation and asthma-like symptoms. Matt Walker, the company’s chief executive and the study’s lead author, told GEN he has lived with severe dog allergy for years and wanted to address the problem at its biological source rather than by trying to manage symptoms.

The researchers used edited canine fibroblasts, then somatic cell nuclear transfer, and report no off-target mutations or large chromosomal changes. They also say the dogs, born in September 2024, have shown normal growth and behaviour so far.

AP reported that commercial rollout remains distant, with safety testing, regulation and breed-to-breed validation still ahead. Bioethicists have also raised the possibility that hypoallergenic pets could affect shelter adoption patterns.

For veterinarians, the broader implication is clear: gene editing is moving from theory towards trait modification in companion animals, and allergy reduction may be one of its first practical uses.

Image Source: Kindred